Pharmasaga Co. Ltd.
Pharmasaga Co. Ltd. (https://www.pharmasaga.com/en/index.aspx), is a drug discovery and development company. It aims to develop novel anti-diabetic small-molecule drugs that can treat and reverse diabetes. Pharamsaga pioneered to study function and mechanism of Pdia4, a master gene that controls β-cell pathogenesis and, in turn, diabetes. Using a rational drug design strategy, combining molecular docking, Pdia4 bioassay, and chemical synthesis, PS1, a Pdia4-based drug candidate, was developed for diabetes. This novel drug precisely targets diabetes and has the potential to become the world’s first curative treatment for diabetes. After receving IND approvals from the USFDA and Taiwanese FDA, PS1 is now on human trials for type 2 diabetes, followed by human trials for type 1 diabetes and pancreatic cancer. Preliminary data showed that PS1 had high safety and great efficacy in decreased blood glucose. Additionally, Orphan Drug Designation (ODD) of PS1 was applied to USFDA.
PharmaJet
PharmaJet’s mission is to enable greater access to life improving pharmaceuticals. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet’s Needle-free Injection Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com.
PharmaCircle
PharmaCircle will be showcasing our Partnership Explorer, a new analysis tool that helps business development professionals to identify external innovation and partnering opportunities. With PharmaCircle’s Partnership Explorer, you can easily explore and evaluate partnered and unpartnered pipeline programs and products by a host of filters including product name, molecule/API name, target name, company name, indication/disease area, molecule/API type, target type, mechanism type, phase, route, country/region, drug delivery category, and dosage form. PharmaCircle’s business intelligence and prospecting tools explore the business portfolios, capabilities, and transactions of more than 32,000 commercial and emerging stage life sciences companies and suppliers from around the world. PharmaCircle’s search and analysis tools include the Partnership Explorer; Terminated Programs Tracker; Strategic Deals Analyzer; Venture Capital & Funding Tracker; Pipeline & Products Intelligence with Formulation Details; Product Sales, Forecast & Unit Pricing Data; Company Profile PDF Reports; Disease Area PDF Reports; Epidemiology Explorer; Trial Landscape Explorer; Patent Exclusivity Tracker; Drug Delivery Technology Analyzer; CMOCRO Explorer; Prospector Business Development Map Tool; Spyglass Personalized Weekly Email News Brief. Since 2003, PharmaCircle has been providing commercial and emerging stage life sciences companies and suppliers the integrated data, powerful analysis tools and industry knowledge needed to solve complex, real-world challenges in product development and innovation. To see how we can help you, please visit our booth #1243 or website www.pharmacircle.com | PharmaCircle will be showcasing Partnership Explorer, a powerful analysis tool that helps business development professionals to identify external innovation and partnering opportunities, and enhancements to our Professional Subscription Service of business intelligence and prospecting solutions. With PharmaCircle’s Partnership Explorer, you can easily explore and evaluate more than 25,000 unpartnered programs and products by a host of filters, identify country/regional licensing opportunities, and track in-licensed and out-licensed products for each company. PharmaCircle’s Professional Subscription Service includes Pipeline & Products Intelligence; Company Profile Reports; Strategic Deals Analysis; Venture Capital & Funding Tracking; Product Sales, Forecast & Pricing; Epidemiology Explorer; Orphan Drug Analytics, Trial Landscape Explorer; Prospector Business Development Map Tool; CMOCRO Explorer; News & Insights; and Spyglass Personalized Weekly Email News Brief. PharmaCircle’s business intelligence and prospecting tools provide a comprehensive view of the business portfolios, capabilities, deals and funding transactions of more than 35,000 commercial and emerging stage life sciences companies and suppliers from around the world. Since 2003, PharmaCircle has been providing commercial and emerging stage life sciences companies and suppliers the integrated data, powerful analysis tools and industry knowledge needed to solve complex, real-world challenges in product development and innovation. To see how we can help you, please visit our booth #4155 or website www.pharmacircle.com. | PharmaCircle provides the curated data, powerful analysis tools and industry knowledge needed to solve complex, real-world challenges in drug product development and innovation. PharmaCircle’s search and evaluation tools identify unpartnered pipeline program opportunities and examine the pipeline/product portfolios and business transactions of commercial and emerging stage life sciences companies and their suppliers. PharmaCircle has been curating pharma pipeline intelligence, formulation/drug delivery information, and supply chain insights for more than 20 years. Our team of product developers and customer support personnel is comprised of scientists and business analysts from the life sciences industry. Many life sciences innovators and manufacturers rely on PharmaCircle’s curated content and expert analyses for mission-critical projects, and reference our data in conference presentations and published articles.
PHARA
x
Pharma in Silica
Pharma in silica is a preclinical-stage company developing a well-tolerated chemotherapy treatment for lung, breast and proprietary drug-development other solid cancers. The company deploys a /manufacture platform based on novel silica-made nanocarriers enhancing safety & efficacy of cytotoxic molecules.
Personalis, Inc
Personalis is transforming the active management of cancer through more personalized testing. Our assays combine tumor-and-normal profiling with proprietary algorithms to deliver the most advanced insights, even as cancer evolves over time. With our industry-leading products, you can detect recurrence at the earliest timepoints, confidently select therapies based on ultra-comprehensive genomic profiling, and enhance your biomarker strategy for drug development. Join us as we redefine precision oncology.
Percival Scientific
Pegasus One
Pegasus One is a custom software development firm specializing in healthcare innovation. We build AI-powered, cloud-native, and interoperable solutions for health systems, payers, life sciences, and startups. Our services include clinical trial platforms, FHIR integration, remote patient monitoring, and workflow automation—driving scalable, secure, and compliant digital transformation with measurable outcomes and lasting impact.
PCI Pharma Services
PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives. | PCI is your world leading CDMO, truly spanning the cycle, connecting development and commercialization, de-risking the supply chain providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of CDMO services. Leading technology and continued investment enable us to address global outsourcing development needs throughout the product lifecycle. PCI offers a global network of innovative centers of excellence for the development, manufacturing, packaging, storage, and distribution of life changing therapies. Our aim is simple, to accelerate your product from development to commercialization as efficiently and cost-effectively as possible. | PCI Pharma is a global CDMO known for delivering seamless integrated end-to-end drug development, manufacturing, and packaging solutions across the product lifecycle with a strong focus on quality, flexibility, and innovation. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of CDMO services. Leading technology and continued investment enable us to address global outsourcing needs throughout the product lifecycle. We operate a global network of innovative centers of excellence for the development, manufacturing, drug-device combination assembly, packaging, storage, and distribution of life-changing therapies. Our world- leading sterile fill-finish and lyophilization capabilities combined with specialist contained manufacturing and packaging facilities dedicated to processing highly potent drug products are complemented by a global network of packaging facilities delivering a truly differentiated service. Our aim is simple, to accelerate your product from development to commercialization as efficiently and cost-effectively as possible.
PatSnap
Patsnap empowers IP and R&D teams by providing better answers, so they can make faster decisions with more confidence. Founded in 2007, Patsnap is the global leader in AI-powered IP and R&D intelligence. Our domain-specific LLM, trained on our extensive proprietary innovation data, pairs seamlessly with our AI assistant, Hiro, to deliver insights that drive results—boosting IP productivity by 75% and cutting R&D wastage by 25%. IP and R&D teams collaborate better with a user-friendly platform across the entire innovation lifecycle. Over 15,000 companies trust Patsnap to innovate faster with AI, including NASA, PayPal, Sanofi, Dow Chemical, and Wilson Sonsini. | Founded in Singapore in 2007, PatSnap is a global leading innovation intelligence company. Leveraging domain-specific AI agents and robust analytics tools, PatSnap empowers IP and R&D teams to unlock insights, accelerate discoveries and protect breakthroughs. Trusted by more than 15,000 enterprises, law firms and research institutions in over 50 countries including one-third of the world’s largest R&D spenders, Patsnap transforms how organizations innovate and make critical decisions. Learn more at www.patsnap.com.